DataSheet_1_Immune Checkpoint LAG3 and Its Ligand FGL1 in Cancer.xlsx (17.75 kB)
Download file

DataSheet_1_Immune Checkpoint LAG3 and Its Ligand FGL1 in Cancer.xlsx

Download (17.75 kB)
posted on 17.01.2022, 04:13 authored by An-Ping Shi, Xi-Yang Tang, Yan-Lu Xiong, Kai-Fu Zheng, Yu-Jian Liu, Xian-Gui Shi, Yao Lv, Tao Jiang, Nan Ma, Jin-Bo Zhao

LAG3 is the most promising immune checkpoint next to PD-1 and CTLA-4. High LAG3 and FGL1 expression boosts tumor growth by inhibiting the immune microenvironment. This review comprises four sections presenting the structure/expression, interaction, biological effects, and clinical application of LAG3/FGL1. D1 and D2 of LAG3 and FD of FGL1 are the LAG3-FGL1 interaction domains. LAG3 accumulates on the surface of lymphocytes in various tumors, but is also found in the cytoplasm in non-small cell lung cancer (NSCLC) cells. FGL1 is found in the cytoplasm in NSCLC cells and on the surface of breast cancer cells. The LAG3-FGL1 interaction mechanism remains unclear, and the intracellular signals require elucidation. LAG3/FGL1 activity is associated with immune cell infiltration, proliferation, and secretion. Cytokine production is enhanced when LAG3/FGL1 are co-expressed with PD-1. IMP321 and relatlimab are promising monoclonal antibodies targeting LAG3 in melanoma. The clinical use of anti-FGL1 antibodies has not been reported. Finally, high FGL1 and LAG3 expression induces EGFR-TKI and gefitinib resistance, and anti-PD-1 therapy resistance, respectively. We present a comprehensive overview of the role of LAG3/FGL1 in cancer, suggesting novel anti-tumor therapy strategies.